Introduction & Objective: Employer based diabetes programs have been created to maximize diabetes related outcomes and increase value based care. The aim of this program is to provide sustained multidisciplinary diabetes education enforcing the ADA Standards of Care to those with our employer based health plan. Waived copays on diabetes medications and supplies was incorporated to increase engagement.

Methods: This ambulatory diabetes program included those 18 years of age or older with diabetes and our employer based health plan. The program is a voluntary, opt-in program. Persons with diabetes included those who enrolled between November 2022 and October 2023. Interventions with recommendations were communicated to the person with diabetes’ providers related to their diabetes and cardiovascular related management. Outcomes related to mean changes in person weight and A1C for those actively engaged in the program were evaluated.

Results: A total of 247 adults were initially enrolled in the employee diabetes program. The baseline A1C was 116 with A1C <7%, 59 with A1C ≥7- ≤ 8%, 30 with A1C > 8- ≤ 9%, and 42 persons with A1C >9% respectively. There were 1,131 initial interventions made in relation to their diabetes and cardiovascular medications/supplies, immunization, preventative medication, laboratory and referral recommendations. In the final outcome analysis, 208 persons were included due to continued active engagement in the program. The mean change in weight from baseline was found to be -1.75 kg (-1.73%) and the mean change in A1C from baseline was -0.94 (-9.71%).

Conclusion: Our employee diabetes program showed a trend toward improved persons with diabetes outcomes with active engagement up to one year. The waived copay financial incentive related to diabetes medications and supplies motivated follow-up engagement and numerically lead to a reduction in weight and A1C values. Further examination is planned for new and those with continued enrollment.

Disclosure

H.A. Habib: None. N. Saad: None. L. Hughes: Advisory Panel; embecta.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.